
KEYNOTE-B96 Trial Shows Keytruda is First Immunotherapy to Improve Overall Survival in Platinum-Resistant Ovarian Cancer
Key Takeaways from the Phase III KEYNOTE-B96/ENGOT-ov65 Trial Keytruda Shows First OS Benefit in Ovarian Cancer: The KEYNOTE-B96 trial marks the first time an immune checkpoint inhibitor—Keytruda (pembrolizumab)—has demonstrated a statistically …